Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin in HER2-expressing advanced breast cancer (Japan)
jRCT2031250207Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in breast cancer, sponsored by Pfizer. Primary endpoint: Objective response (OR) by investigator assessment. Started Aug 2025; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031250207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250207.